Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
LifeSci Venture Partners is a New York-based venture capital firm founded in 2017, specializing in the biopharmaceutical sector. The firm leverages collective clinical, scientific, and investment expertise to support companies aiming to reshape medical care and the healthcare system. LifeSci Venture Partners is part of the broader LifeSci ecosystem, which includes LifeSci Advisors and LifeSci Capital, providing integrated access to public markets infrastructure.
As of now, LifeSci Venture Partners manages a portfolio of 10 companies, focusing on clinical-stage opportunities that have achieved proof-of-concept and are preparing to transition to the public market within 12-18 months. The firm emphasizes investments in innovative approaches to molecular medicine, technology, and healthcare delivery.
LifeSci Venture Partners has established itself as a significant player in the healthcare investment space, with a strong emphasis on transformational biopharmaceutical advancements. The firm’s connections within the LifeSci ecosystem enhance the growth potential of its investments, allowing for strategic guidance and support in navigating the complexities of clinical development.
LifeSci Venture Partners primarily invests in clinical-stage biopharmaceutical companies that have achieved proof-of-concept data. The firm targets investments in Series A, Series B, and Pre-IPO stages, with a strong emphasis on companies expected to go public within 12-18 months of investment. Their investment strategy focuses on sectors such as biotech and healthcare, particularly in areas innovating molecular medicine, technology, and healthcare delivery.
The firm seeks to partner with companies that are developing transformational advancements in biopharmaceuticals. LifeSci Venture Partners looks for founders who demonstrate a strong vision and capability to navigate the complexities of clinical development and public market transitions. The firm’s integration with LifeSci Capital and LifeSci Advisors provides a differentiated pathway for portfolio companies to access public markets, enhancing their growth potential.
LifeSci Venture Partners has a diverse portfolio of 10 companies, focusing on innovative biopharmaceutical solutions. Notable portfolio companies include:
LifeSci Venture Partners has also achieved notable exits with companies like Erasca and Caribou Biosciences, showcasing its ability to guide portfolio companies through successful public market transitions.
Paul Yook: Managing Partner & CIO. Paul has extensive experience in the biopharmaceutical sector and has led numerous successful investments.
Ryan Cinalli, Ph.D.: Partner & CSO. Ryan brings a strong scientific background and has been instrumental in evaluating clinical-stage opportunities.
Ira Kalfus, M.D.: Venture Partner. Ira has a medical background and provides valuable insights into clinical development processes.
Brittany Amendola, C.P.A.: Chief Financial Officer. Brittany oversees financial operations and ensures fiscal responsibility within the firm.
Jeff Seo: Business Development. Jeff focuses on expanding the firm's network and identifying new investment opportunities.
To pitch LifeSci Venture Partners, founders should visit their official website at LifeSci Venture Partners. It is recommended to include a comprehensive pitch deck that outlines the clinical stage of the company, proof-of-concept data, and the market opportunity. Founders should expect a response within a few weeks, and warm introductions are preferred but not mandatory.
In recent months, LifeSci Venture Partners has continued to make strides in the biopharmaceutical sector. Notable portfolio companies like Erasca and Caribou Biosciences have successfully transitioned to public markets, showcasing the firm's effective investment strategy.
As of September 2023, LifeSci Venture Partners has been actively involved in supporting its portfolio companies through their clinical development phases, with a focus on innovative therapies. The firm has also been expanding its presence in the Asia-Pacific region, enhancing its global reach.
What investment criteria does LifeSci Venture Partners look for?
LifeSci Venture Partners focuses on clinical-stage biopharmaceutical companies that have achieved proof-of-concept data. They primarily invest in Series A, Series B, and Pre-IPO stages, targeting companies expected to go public within 12-18 months.
How can I pitch to LifeSci Venture Partners?
Founders can submit their pitches through the official website at LifeSci Venture Partners. It is advisable to include detailed information about the company's clinical stage, proof-of-concept data, and market potential in the pitch deck.
What makes LifeSci Venture Partners different from other investors?
The firm is uniquely integrated within the LifeSci ecosystem, which includes LifeSci Advisors and LifeSci Capital. This integration provides portfolio companies with enhanced access to public markets and investor relations support.
What is the geographic focus of LifeSci Venture Partners?
LifeSci Venture Partners primarily invests in companies based in the United States, focusing on the biopharmaceutical sector.
What kind of post-investment involvement can founders expect?
LifeSci Venture Partners provides strategic guidance and support to its portfolio companies, helping them navigate clinical development and public market transitions. Their deep expertise in the biopharmaceutical sector adds significant value to their investments.
What is the average check size for investments?
While specific check sizes are not publicly disclosed, the average round size across reported investments is approximately $64.8 million.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.